1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Esophageal Cancer Molecular Diagnosis Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Esophageal Cancer Molecular Diagnosis Market, by Technology
8.1.1. Polymerase Chain Reaction (PCR)
8.1.1.1. Market Revenue and Forecast
8.1.2. Next-Generation Sequencing (NGS)
8.1.2.1. Market Revenue and Forecast
8.1.3. Fluorescence In Situ Hybridization (FISH)
8.1.3.1. Market Revenue and Forecast
8.1.4. Immunohistochemistry (IHC)
8.1.4.1. Market Revenue and Forecast
8.1.5. Microarray
8.1.5.1. Market Revenue and Forecast
8.1.6. Liquid Biopsy
8.1.6.1. Market Revenue and Forecast
8.1.7. Sanger Sequencing
8.1.7.1. Market Revenue and Forecast 8.1.8. Others
8.1.8.1. Market Revenue and Forecast
9.1. Esophageal Cancer Molecular Diagnosis Market, by Biomarker Type
9.1.1. Genetic Markers (e.g., TP53, KRAS, EGFR, HER2)
9.1.1.1. Market Revenue and Forecast
9.1.2. Epigenetic Markers (e.g., DNA methylation)
9.1.2.1. Market Revenue and Forecast
9.1.3. Protein Biomarkers (e.g., p53, Ki-67, PD-L1)
9.1.3.1. Market Revenue and Forecast
9.1.4. Circulating Tumor DNA (ctDNA)
9.1.4.1. Market Revenue and Forecast
9.1.5. Circulating Tumor Cells (CTCs)
9.1.5.1. Market Revenue and Forecast
9.1.6. MicroRNA
9.1.6.1. Market Revenue and Forecast
9.1.7. Others
9.1.7.1. Market Revenue and Forecast
10.1. Esophageal Cancer Molecular Diagnosis Market, by Cancer Type
10.1.1. Esophageal Adenocarcinoma
10.1.1.1. Market Revenue and Forecast
10.1.2. Esophageal Squamous Cell Carcinoma
10.1.2.1. Market Revenue and Forecast
10.1.3. Others (e.g., small cell carcinoma, sarcomatoid carcinoma)
10.1.3.1. Market Revenue and Forecast
11.1. Esophageal Cancer Molecular Diagnosis Market, by Sample Type
11.1.1. Tissue Biopsy
11.1.1.1. Market Revenue and Forecast
11.1.2. Blood (Liquid Biopsy)
11.1.2.1. Market Revenue and Forecast
11.1.3. Saliva
11.1.3.1. Market Revenue and Forecast
11.1.4. Others (e.g., urine, gastric lavage)
11.1.4.1. Market Revenue and Forecast
12.1. Esophageal Cancer Molecular Diagnosis Market, by Application
12.1.1. Early Detection/Screening
12.1.1.1. Market Revenue and Forecast
12.1.2. Prognostic Testing
12.1.2.1. Market Revenue and Forecast
12.1.3. Companion Diagnostics (Therapy Selection)
12.1.3.1. Market Revenue and Forecast
12.1.4. Recurrence Monitoring
12.1.4.1. Market Revenue and Forecast
12.1.5. Research Use
12.1.5.1. Market Revenue and Forecast
12.1.6. Others
12.1.6.1. Market Revenue and Forecast
13.1. Esophageal Cancer Molecular Diagnosis Market, by End User
13.1.1. Hospitals
13.1.1.1. Market Revenue and Forecast
13.1.2. Cancer Research Institutes
13.1.2.1. Market Revenue and Forecast
13.1.3. Diagnostic Laboratories
13.1.3.1. Market Revenue and Forecast
13.1.4. Academic & Research Centers
13.1.4.1. Market Revenue and Forecast
13.1.5. Others
13.1.5.1. Market Revenue and Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by Technology
14.1.2. Market Revenue and Forecast, by Biomarker Type
14.1.3. Market Revenue and Forecast, by Cancer Type
14.1.4. Market Revenue and Forecast, by Sample Type
14.1.5. Market Revenue and Forecast, by Application
14.1.6. Market Revenue and Forecast, by End User
14.1.7. U.S.
14.1.7.1. Market Revenue and Forecast, by Technology
14.1.7.2. Market Revenue and Forecast, by Biomarker Type
14.1.7.3. Market Revenue and Forecast, by Cancer Type
14.1.7.4. Market Revenue and Forecast, by Sample Type
14.1.8. Market Revenue and Forecast, by Application
14.1.8.1. Market Revenue and Forecast, by End User
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Technology
14.1.9.2. Market Revenue and Forecast, by Biomarker Type
14.1.9.3. Market Revenue and Forecast, by Cancer Type
14.1.9.4. Market Revenue and Forecast, by Sample Type
14.1.10. Market Revenue and Forecast, by Application
14.1.11. Market Revenue and Forecast, by End User
14.2. Europe
14.2.1. Market Revenue and Forecast, by Technology
14.2.2. Market Revenue and Forecast, by Biomarker Type
14.2.3. Market Revenue and Forecast, by Cancer Type
14.2.4. Market Revenue and Forecast, by Sample Type
14.2.5. Market Revenue and Forecast, by Application
14.2.6. Market Revenue and Forecast, by End User
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Technology
14.2.8.2. Market Revenue and Forecast, by Biomarker Type
14.2.8.3. Market Revenue and Forecast, by Cancer Type
14.2.9. Market Revenue and Forecast, by Sample Type
14.2.10. Market Revenue and Forecast, by Application
14.2.10.1. Market Revenue and Forecast, by End User
14.2.11. Germany
14.2.11.1. Market Revenue and Forecast, by Technology
14.2.11.2. Market Revenue and Forecast, by Biomarker Type
14.2.11.3. Market Revenue and Forecast, by Cancer Type
14.2.12. Market Revenue and Forecast, by Sample Type
14.2.13. Market Revenue and Forecast, by Application
14.2.14. Market Revenue and Forecast, by End User
14.2.15. France
14.2.15.1. Market Revenue and Forecast, by Technology
14.2.15.2. Market Revenue and Forecast, by Biomarker Type
14.2.15.3. Market Revenue and Forecast, by Cancer Type
14.2.15.4. Market Revenue and Forecast, by Sample Type
14.2.16. Market Revenue and Forecast, by Application
14.2.16.1. Market Revenue and Forecast, by End User
14.2.17. Rest of Europe
14.2.17.1. Market Revenue and Forecast, by Technology
14.2.17.2. Market Revenue and Forecast, by Biomarker Type
14.2.17.3. Market Revenue and Forecast, by Cancer Type
14.2.17.4. Market Revenue and Forecast, by Sample Type
14.2.18. Market Revenue and Forecast, by Application
14.2.18.1. Market Revenue and Forecast, by End User
14.3. APAC
14.3.1. Market Revenue and Forecast, by Technology
14.3.2. Market Revenue and Forecast, by Biomarker Type
14.3.3. Market Revenue and Forecast, by Cancer Type
14.3.4. Market Revenue and Forecast, by Sample Type
14.3.5. Market Revenue and Forecast, by Application
14.3.6. Market Revenue and Forecast, by End User
14.3.7. India
14.3.7.1. Market Revenue and Forecast, by Technology
14.3.7.2. Market Revenue and Forecast, by Biomarker Type
14.3.7.3. Market Revenue and Forecast, by Cancer Type
14.3.7.4. Market Revenue and Forecast, by Sample Type
14.3.8. Market Revenue and Forecast, by Application
14.3.9. Market Revenue and Forecast, by End User
14.3.10. China
14.3.10.1. Market Revenue and Forecast, by Technology
14.3.10.2. Market Revenue and Forecast, by Biomarker Type
14.3.10.3. Market Revenue and Forecast, by Cancer Type
14.3.10.4. Market Revenue and Forecast, by Sample Type
14.3.11. Market Revenue and Forecast, by Application
14.3.11.1. Market Revenue and Forecast, by End User
14.3.12. Japan
14.3.12.1. Market Revenue and Forecast, by Technology
14.3.12.2. Market Revenue and Forecast, by Biomarker Type
14.3.12.3. Market Revenue and Forecast, by Cancer Type
14.3.12.4. Market Revenue and Forecast, by Sample Type
14.3.12.5. Market Revenue and Forecast, by Application
14.3.12.6. Market Revenue and Forecast, by End User
14.3.13. Rest of APAC
14.3.13.1. Market Revenue and Forecast, by Technology
14.3.13.2. Market Revenue and Forecast, by Biomarker Type
14.3.13.3. Market Revenue and Forecast, by Cancer Type
14.3.13.4. Market Revenue and Forecast, by Sample Type
14.3.13.5. Market Revenue and Forecast, by Application
14.3.13.6. Market Revenue and Forecast, by End User
14.4. MEA
14.4.1. Market Revenue and Forecast, by Technology
14.4.2. Market Revenue and Forecast, by Biomarker Type
14.4.3. Market Revenue and Forecast, by Cancer Type
14.4.4. Market Revenue and Forecast, by Sample Type
14.4.5. Market Revenue and Forecast, by Application
14.4.6. Market Revenue and Forecast, by End User
14.4.7. GCC
14.4.7.1. Market Revenue and Forecast, by Technology
14.4.7.2. Market Revenue and Forecast, by Biomarker Type
14.4.7.3. Market Revenue and Forecast, by Cancer Type
14.4.7.4. Market Revenue and Forecast, by Sample Type
14.4.8. Market Revenue and Forecast, by Application
14.4.9. Market Revenue and Forecast, by End User
14.4.10. North Africa
14.4.10.1. Market Revenue and Forecast, by Technology
14.4.10.2. Market Revenue and Forecast, by Biomarker Type
14.4.10.3. Market Revenue and Forecast, by Cancer Type
14.4.10.4. Market Revenue and Forecast, by Sample Type
14.4.11. Market Revenue and Forecast, by Application
14.4.12. Market Revenue and Forecast, by End User
14.4.13. South Africa
14.4.13.1. Market Revenue and Forecast, by Technology
14.4.13.2. Market Revenue and Forecast, by Biomarker Type
14.4.13.3. Market Revenue and Forecast, by Cancer Type
14.4.13.4. Market Revenue and Forecast, by Sample Type
14.4.13.5. Market Revenue and Forecast, by Application
14.4.13.6. Market Revenue and Forecast, by End User
14.4.14. Rest of MEA
14.4.14.1. Market Revenue and Forecast, by Technology
14.4.14.2. Market Revenue and Forecast, by Biomarker Type
14.4.14.3. Market Revenue and Forecast, by Cancer Type
14.4.14.4. Market Revenue and Forecast, by Sample Type
14.4.14.5. Market Revenue and Forecast, by Application
14.4.14.6. Market Revenue and Forecast, by End User
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Technology
14.5.2. Market Revenue and Forecast, by Biomarker Type
14.5.3. Market Revenue and Forecast, by Cancer Type
14.5.4. Market Revenue and Forecast, by Sample Type
14.5.5. Market Revenue and Forecast, by Application
14.5.6. Market Revenue and Forecast, by End User
14.5.7. Brazil
14.5.7.1. Market Revenue and Forecast, by Technology
14.5.7.2. Market Revenue and Forecast, by Biomarker Type
14.5.7.3. Market Revenue and Forecast, by Cancer Type
14.5.7.4. Market Revenue and Forecast, by Sample Type
14.5.8. Market Revenue and Forecast, by Application
14.5.8.1. Market Revenue and Forecast, by End User
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Technology
14.5.9.2. Market Revenue and Forecast, by Biomarker Type
14.5.9.3. Market Revenue and Forecast, by Cancer Type
14.5.9.4. Market Revenue and Forecast, by Sample Type
14.5.9.5. Market Revenue and Forecast, by Application
14.5.9.6. Market Revenue and Forecast, by End User
15.1. Roche Diagnostics
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. QIAGEN
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. Invitae Corporation
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. BGI Genomics
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. Myriad Genetics
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. Natera
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. NeoGenomics Laboratories
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. F. Hoffmann-La Roche Ltd,
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. Danaher Corporation (Leica Biosystems & Cepheid),
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. Biocartis Group NV.
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
17.1. About Us
17.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client